TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10205312

Group type: EXPERIMENTAL
Intervention: Intralipid 30%
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intralipid 10%
Number of subjects: 16
Study: 8019763

Group type: EXPERIMENTAL
Intervention: Intravenous lithium (4 mEq kg‐1) in normal rats
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous lithium (4 mEq kg‐1) in diabetic rats
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous glucose (0.5 g kg‐1) in lithium-treated diabetic rats
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous glucose (0.5 g kg‐1) in normal rats
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous glucose (0.5 g kg‐1) in both groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lithium treatment in both normal and diabetic rats
Number of subjects: 0
Study: 3217222

Group type: EXPERIMENTAL
Intervention: 30% heart-rate reserve
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 60% heart-rate reserve
Number of subjects: 24
Study: 30804032

Group type: EXPERIMENTAL
Intervention: Patient-directed decision support strategies (Decision Aids - DAs)
Number of subjects: 1120

Group type: EXPERIMENTAL
Intervention: Physician-directed decision support strategies (Decision Aids - DAs)
Number of subjects: 1120

Group type: EXPERIMENTAL
Intervention: Surgeons receiving a report detailing patients' goals and treatment preferences
Number of subjects: 1120

Group type: COMPARATOR
Intervention: Surgeons not receiving a report detailing patients' goals and treatment preferences
Number of subjects: 1120
Study: 27264198

Group type: EXPERIMENTAL
Intervention: Clonidine (0.1 mg TID, increased to 0.2 mg TID if hemodynamics stable)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 26742732

Group type: EXPERIMENTAL
Intervention: TomoTherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: LINAC-IMRT
Number of subjects: 60
Study: 23745526

Group type: EXPERIMENTAL
Intervention: Arformoterol aerosol solution (15μg/2mL) via nebulizer
Number of subjects: 20

Group type: COMPARATOR
Intervention: Salmeterol dry powder (50μg) via Diskus
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Patient preference
Number of subjects: 20
Study: 21958534

Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 18588736

Group type: EXPERIMENTAL
Intervention: ganciclovir 10 mg/kg bodyweight for 21 days
Number of subjects: 23

Group type: COMPARATOR
Intervention: Observation without therapy
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: ganciclovir therapy
Number of subjects: 23
Study: 17893906

Group type: EXPERIMENTAL
Intervention: Kattan-nomogram for prediction of indolent prostate cancer
Number of subjects: 825

Group type: EXPERIMENTAL
Intervention: Cancers found at repeated screening after 4 years
Number of subjects: 825
Study: 15136936

Group type: EXPERIMENTAL
Intervention: Magnification endoscopy for normal EGJ
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Magnification endoscopy for CLE
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Methylene blue staining
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Magnification endoscopy
Number of subjects: 88
Study: 12430728

Group type: EXPERIMENTAL
Intervention: Moisturizer applied once daily for 3 weeks
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Moisturizer applied twice daily for 3 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Moisturizer (both dosages)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (untreated regional area)
Number of subjects: 19
Study: 9820354

Group type: EXPERIMENTAL
Intervention: 750 mg oral ciprofloxacin
Number of subjects: 22

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 22
Study: 7697147

Group type: EXPERIMENTAL
Intervention: Ankle block in addition to general anesthesia
Number of subjects: 40

Group type: COMPARATOR
Intervention: General anesthesia alone (Control)
Number of subjects: 40
Study: 2575975

Group type: EXPERIMENTAL
Intervention: 200mg tablet
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 200mg in solution
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 5mg intravenously
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 200mg tablet with food
Number of subjects: 12
Study: 321067

Group type: EXPERIMENTAL
Intervention: Vaccination with BCG and autologous irradiated cells
Number of subjects: 15

Group type: COMPARATOR
Intervention: Conservative treatment (Control)
Number of subjects: 15
Study: 31483964

Group type: EXPERIMENTAL
Intervention: Mitapivat 50 mg twice daily
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Mitapivat 300 mg twice daily
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Mitapivat (both dosages)
Number of subjects: 52
Study: 27304428

Group type: EXPERIMENTAL
Intervention: Ustekinumab (n=16)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (n=17)
Number of subjects: 33
Study: 26065433

Group type: EXPERIMENTAL
Intervention: OROS-methylphenidate
Number of subjects: 255

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study: 23843589

Group type: EXPERIMENTAL
Intervention: Antibacterial honey applied at the exit site
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard topical application of mupirocin
Number of subjects: 0
Study: 21734059

Group type: EXPERIMENTAL
Intervention: Total SFA
Number of subjects: 1032

Group type: EXPERIMENTAL
Intervention: Total cis PUFA
Number of subjects: 1032

Group type: EXPERIMENTAL
Intervention: Cis (n-3) PUFA
Number of subjects: 1032

Group type: EXPERIMENTAL
Intervention: PS ratio (PUFA:SFA)
Number of subjects: 1032

Group type: EXPERIMENTAL
Intervention: Obesity-related metabolic factors adjustment
Number of subjects: 1032
Study: 19848546

Group type: EXPERIMENTAL
Intervention: Mindfulness-based breathing therapy (MBBT)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Support group
Number of subjects: 86
Study: 16769401

Group type: EXPERIMENTAL
Intervention: Digital intubation (DI)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Laryngoscope intubation (LI)
Number of subjects: 2
Study: 15609886

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day
Number of subjects: 48

Group type: COMPARATOR
Intervention: Vitamin C 500 mg/day
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 11376310

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 5053

Group type: COMPARATOR
Intervention: Older statins
Number of subjects: 5053

Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy
Number of subjects: 5053
Study: 9369869

Group type: EXPERIMENTAL
Intervention: Pediatric quality of care indicators
Number of subjects: 557
Study: 7926408

Group type: EXPERIMENTAL
Intervention: Single oral dose of ivermectine (200 mcg/Kg)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 3096764

Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate (1.5 mg/Kg/day) for 18 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31343789

Group type: EXPERIMENTAL
Intervention: Pretreatment PTSD symptom networks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mean severity of symptoms at pretreatment
Number of subjects: 0
Study: 29950456

Group type: EXPERIMENTAL
Intervention: BLISS (modified baby-led weaning)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Control (traditional spoon-feeding)
Number of subjects: 206
Study: 27721228

Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg/d
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 24781374

Group type: EXPERIMENTAL
Intervention: Web-based CAPS intervention
Number of subjects: 132
Study: 21450587

Group type: EXPERIMENTAL
Intervention: Intensive implementation programme for pharmacists
Number of subjects: 100

Group type: COMPARATOR
Intervention: Educational manual for pharmacists (Control)
Number of subjects: 100
Study: 15828614

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transdermic route for administration of estrogens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Progestins
Number of subjects: 0
Study: 12144586

Group type: EXPERIMENTAL
Intervention: Prucalopride 1 mg daily for 4 weeks
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 11279910

Group type: EXPERIMENTAL
Intervention: Adult-onset headache (onset at or after age 20)
Number of subjects: 1013

Group type: EXPERIMENTAL
Intervention: Common circumstances of headache onset in adult-onset chronic headache
Number of subjects: 1013

Group type: EXPERIMENTAL
Intervention: Common factors in adult-onset chronic headache
Number of subjects: 1013

Group type: EXPERIMENTAL
Intervention: Other factors in adult-onset chronic headache
Number of subjects: 1013
Study: 7596697

Group type: EXPERIMENTAL
Intervention: Encopretic patients consuming Ensure meal after overnight fast
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group consuming Ensure meal after overnight fast
Number of subjects: 10
Study: 2351011

Group type: EXPERIMENTAL
Intervention: Bread (GI 100)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Rice (GI 79)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Spaghetti (GI 61)
Number of subjects: 12
Study: 381124

Group type: EXPERIMENTAL
Intervention: Transfer factor
Number of subjects: 33

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 33
Study: 31980242

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided access
Number of subjects: 635

Group type: COMPARATOR
Intervention: Fluoroscopy-guided access
Number of subjects: 635
Study: 28833942

Group type: COMPARATOR
Intervention: MTA
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: MTA/TDM
Number of subjects: 33
Study: 28445354

Group type: EXPERIMENTAL
Intervention: Tumescent saline solution with epinephrine (1:1 million) and lidocaine (0.05%) (group 2)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Tumescent saline solution with epinephrine (1:1 million) (group 1)
Number of subjects: 40
Study: 26626301

Group type: EXPERIMENTAL
Intervention: Probiotics intervention (tablet A and tablet B)
Number of subjects: 200
Study: 24005139

Group type: EXPERIMENTAL
Intervention: Non steroid cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrocortisone Butyrate 0.1% Cream
Number of subjects: 0
Study: 21958789

Group type: EXPERIMENTAL
Intervention: Continuous flow LVAD (trial group)
Number of subjects: 1982

Group type: EXPERIMENTAL
Intervention: Continuous flow LVAD (posttrial group)
Number of subjects: 1982

Group type: EXPERIMENTAL
Intervention: Continuous flow LVAD (both groups)
Number of subjects: 1982
Study: 18245767

Group type: EXPERIMENTAL
Intervention: Integrated Care (IC)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Enhanced Specialty Referral (ESR)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Both IC and ESR
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Problem drinkers
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Nonproblematic drinkers
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 258
Study: 17154745

Group type: EXPERIMENTAL
Intervention: Stage‐matched manuals (MAN)
Number of subjects: 2054

Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy plus manuals (NRT + MAN)
Number of subjects: 2054

Group type: EXPERIMENTAL
Intervention: Expert system plus NRT and manuals (EXP + NRT + MAN)
Number of subjects: 2054

Group type: EXPERIMENTAL
Intervention: Automated counseling plus NRT, manuals, and expert system (TEL + EXP + NRT + MAN)
Number of subjects: 2054
Study: 12649521

Group type: EXPERIMENTAL
Intervention: 8.8 hours of therapy per week for 11.2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Approximately 2 hours of therapy per week for 22.9 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total of 98.4 hours of therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Total of 43.6 hours of therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total length of therapy time
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mean change in Porch Index of Communicative Abilities (PICA) scores
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hours of therapy provided in a week
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total number of hours of therapy
Number of subjects: 0
Study: 16104368

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9021334

Group type: EXPERIMENTAL
Intervention: Hypnotherapy (HT)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Group Therapy (GT)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Individual Desensitization (SD)
Number of subjects: 25
Study: 1576048

Group type: EXPERIMENTAL
Intervention: ICI 170,809 (7 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: ICI 170,809 (15 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: ICI 170,809 (30 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: ICI 170,809 (3 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 2416331

Group type: EXPERIMENTAL
Intervention: Tofisopam (100 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Midazolam (15 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 31878961

Group type: EXPERIMENTAL
Intervention: Aerobic interval training (AIT) on a cycle ergometer at home, three times a week for 8 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group receiving an educational intervention and continuing usual treatment
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Aerobic interval training (AIT)
Number of subjects: 20
Study: 29431785

Group type: EXPERIMENTAL
Intervention: Glucono‐δ‐lactone (GDL) 2000 mg day‐1
Number of subjects: 40
Study: 27559939

Group type: EXPERIMENTAL
Intervention: 10 weeks of physical-cognitive-mindfulness training
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 112
Study: 24440666

Group type: EXPERIMENTAL
Intervention: Laryngeal mask Supreme (LMA-S)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Facemask
Number of subjects: 150

Group type: COMPARATOR
Intervention: Laryngeal tube suction-disposable (LTS-D)
Number of subjects: 150
Study: 22732470

Group type: EXPERIMENTAL
Intervention: Positively Smoke Free (PSF) intervention
Number of subjects: 145

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Attendance of >=7 sessions
Number of subjects: 145
Study: 20157833

Group type: EXPERIMENTAL
Intervention: Ketamine 10 mg kg(‐1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Fentanyl 5 microg kg(‐1) + droperidol 100 microg kg(‐1)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Saline 0.2 ml kg(‐1)
Number of subjects: 120
Study: 17899361

Group type: EXPERIMENTAL
Intervention: Self-regulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Peer deviance
Number of subjects: 0
Study: 15856042

Group type: EXPERIMENTAL
Intervention: 5-FU plus LEV
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: 5-FU plus IFN
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: 5-FU, LEV, and IFN
Number of subjects: 598
Study: 12090963

Group type: EXPERIMENTAL
Intervention: Newly enrolled peer leaders
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Repeat peer leaders
Number of subjects: 235

Group type: COMPARATOR
Intervention: Comparison youth
Number of subjects: 235
Study: 10599933

Group type: EXPERIMENTAL
Intervention: Valerian root extract (VRE) 600 mg LI 156
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Flunitrazepam (FNZ) 1 mg
Number of subjects: 102
Study: 8944542

Group type: EXPERIMENTAL
Intervention: 100% O2
Number of subjects: 20

Group type: COMPARATOR
Intervention: 2.5% CO2 with oxygen
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 5% CO2 with oxygen
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 8% CO2 with oxygen
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 90% O2 + 10% CO2
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 5% and 8% CO2 with oxygen
Number of subjects: 20
Study: 1742480

Group type: EXPERIMENTAL
Intervention: 2.0 megaunits (MU)/m2 of human lymphoblastoid interferon-alpha
Number of subjects: 138

Group type: COMPARATOR
Intervention: 0.2 MU/m2 of human lymphoblastoid interferon-alpha
Number of subjects: 138
Study: 7015844

Group type: EXPERIMENTAL
Intervention: Cimetidine plus antacid (Maalox)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo plus antacid (Maalox)
Number of subjects: 70
Study: 30570071

Group type: EXPERIMENTAL
Intervention: FFR
Number of subjects: 69

Group type: COMPARATOR
Intervention: ANGIO
Number of subjects: 69
Study: 26914525

Group type: EXPERIMENTAL
Intervention: Bespoke physiotherapy intervention
Number of subjects: 21
Study: 25173770

Group type: EXPERIMENTAL
Intervention: Valerian root extract (530 mg per capsule, 1,060 mg daily)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Valerian root extract
Number of subjects: 61
Study: 23736751

Group type: EXPERIMENTAL
Intervention: TIMT + treatment as usual (TAU)
Number of subjects: 400

Group type: COMPARATOR
Intervention: TAU-only
Number of subjects: 400
Study: 21244643

Group type: EXPERIMENTAL
Intervention: Nasal airflow-inducing manoeuvre (NAIM)
Number of subjects: 25
Study: 19739345

Group type: EXPERIMENTAL
Intervention: Lynn's technique (LT)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Minimally invasive approach (MI)
Number of subjects: 56
Study: 17908058

Group type: EXPERIMENTAL
Intervention: Fall prevention program
Number of subjects: 272

Group type: COMPARATOR
Intervention: Health education program (control)
Number of subjects: 272
Study: 15481447

Group type: EXPERIMENTAL
Intervention: PBSC collection after intermediate-dose cytarabine and mitoxantrone (group B)
Number of subjects: 75

Group type: COMPARATOR
Intervention: PBSC collection after induction and/or consolidation chemotherapy (group A)
Number of subjects: 75
Study: 11531012

Group type: EXPERIMENTAL
Intervention: Oltipraz 125 mg/m2
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Oltipraz 250 mg/m2
Number of subjects: 14
Study: 9642024

Group type: EXPERIMENTAL
Intervention: Contralateral visual field presentation of distractor words and color targets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ipsilateral visual field presentation of distractor words and color targets
Number of subjects: 0
Study: 8029811

Group type: EXPERIMENTAL
Intervention: Antithrombin III concentrates (1,500 IU)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study: 2731461

Group type: EXPERIMENTAL
Intervention: Mixed meal containing 60 g complex carbohydrates
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Mixed meal containing 80 g complex carbohydrates
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Mixed meal containing 140 g complex carbohydrates
Number of subjects: 7
Study: 30987685

Group type: EXPERIMENTAL
Intervention: m-health medication adherence intervention
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 18
Study: 29324248

Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg twice daily
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 27333913

Group type: EXPERIMENTAL
Intervention: High Volume (HV) protocol: 70% 1-RM for sets of 10-12 repetitions with 1-min rest
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High Intensity (HI) protocol: 90% 1-RM for sets of 3-5 repetitions with 3-min rest
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group not applicable
Number of subjects: 10
Study: 25422825

Group type: EXPERIMENTAL
Intervention: 6-mm long implants
Number of subjects: 24

Group type: COMPARATOR
Intervention: 10-mm long implants
Number of subjects: 24
Study: 23194203

Group type: EXPERIMENTAL
Intervention: Propofol (25.5 µg/kg/minute)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.54 µg/kg/hour)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 8
Study: 20576945

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 299

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 299
Study: 18831890

Group type: EXPERIMENTAL
Intervention: 5% tramadol plus adrenaline
Number of subjects: 20

Group type: COMPARATOR
Intervention: 2% lidocaine plus adrenaline
Number of subjects: 20
Study: 15834304

Group type: EXPERIMENTAL
Intervention: Polymyxin B-immobilized endotoxin removal hemoperfusion cartridge (PMX) for 2 hours (n = 17)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard therapy (n = 19)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Polymyxin B-immobilized endotoxin removal hemoperfusion cartridge (PMX)
Number of subjects: 36
Study: 11501687

Group type: EXPERIMENTAL
Intervention: Olanzapine (7.9±2.5 mg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Haloperidol (1.4±0.7 mg/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 12
Study: 9237140

Group type: EXPERIMENTAL
Intervention: Panavia resin cement
Number of subjects: 40

Group type: COMPARATOR
Intervention: Zinc phosphate cement
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Other two resin cements (not specified)
Number of subjects: 40
Study: 8244516

Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg PO TID for 7 days)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 3306095

Group type: EXPERIMENTAL
Intervention: Dialysate containing acetate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dialysate containing bicarbonate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dialysate containing glucose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dialysate without glucose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dialysate containing bicarbonate and glucose
Number of subjects: 0
Study: 2700702

Group type: EXPERIMENTAL
Intervention: Bromelaine (3 x 80 mg daily for 6 days)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 30651161

Group type: EXPERIMENTAL
Intervention: Microtracers™ incorporated into base animal feeds and feed additives during production runs.
Number of subjects: 72
Study: 28140752

Group type: EXPERIMENTAL
Intervention: DTaP-sIPV and RV5 concomitantly (Group 1)
Number of subjects: 192

Group type: COMPARATOR
Intervention: DTaP-sIPV and RV5 separately (Group 2)
Number of subjects: 192